OSSFF (Embla Medical hf) ROCE %: 6.91% (As of Mar. 2026)


OSSFF Embla Medical hf OSSFF
92 GF Score
Price $4.15
GF Value $5.49
! 2 Warning Signs
View Full Analysis

What is Embla Medical hf ROCE %?

Embla Medical hf OSSFF 92 ROCE % is 6.91% as of Mar. 2026. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.49. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Embla Medical hf's annualized ROCE % for the quarter that ended in Mar. 2026 was 6.91%.

Embla Medical hf  (OTCPK:OSSFF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Embla Medical hf ROCE % Related Terms

Embla Medical hf ROCE % Historical Data

* Premium members only.

The historical data trend for Embla Medical hf's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embla Medical hf ROCE % Chart

Embla Medical hf Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.07 6.27 8.25 9.04 9.27

Embla Medical hf Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.25 9.45 11.12 9.74 6.91
OSSFF
92GF Score
Embla Medical hf OSSFF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Embla Medical hf ROCE % Calculation

Embla Medical hf's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=127.46/( ( (1538.965 - 209.284) + (1730.491 - 309.571) )/ 2 )
=127.46/( (1329.681+1420.92)/ 2 )
=127.46/1375.3005
=9.27 %

Embla Medical hf's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=95.292/( ( (1730.491 - 309.571) + (1709.095 - 373.087) )/ 2 )
=95.292/( ( 1420.92 + 1336.008 )/ 2 )
=95.292/1378.464
=6.91 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 6.91% mean?
Embla Medical hf (OSSFF) has a ROCE % of 6.91% as of Mar. 2026.
Is Embla Medical hf's ROCE % too high?
Embla Medical hf's current ROCE % is 6.91%. The Medical Devices & Instruments industry median ROCE % is 2.23. Embla Medical hf's value of 6.91% is 209.9% above this industry median. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's ROCE % compare to ABT and SYK?
Embla Medical hf's ROCE % of 6.91% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Embla Medical hf's value of 6.91% is 209.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current ROCE % of 6.91% is 209.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current ROCE % is 6.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current ROCE % of 6.91%. The stock's GF Value™ is $5.49, compared to a current price of $4.15 — trading 24.4% below its estimated fair value. The current ROCE % is 6.91% and 209.9% above the Medical Devices & Instruments industry median of 2.23. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current ROCE % is 6.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embla Medical hf (OSSFF) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of $4.15 is trading 24.4% below its estimated GF Value™ of $5.49.

Key valuation signals for OSSFF:

  • ROCE %: 6.91%
  • GF Value™: $5.49 vs. price of $4.15 (24.4% below fair value)
  • GF Score™: 92/100 with 2 warning signs
  • Industry Position: 209.9% above the Medical Devices & Instruments median

No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embla Medical hf Business Description

Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score

Get the complete analysis for OSSFF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.15
Price
$5.49
GF Value